Izotropic Corporation's (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System

Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the AI-driven imaging sector targeting the breast cancer market [1][2] Industry Overview - The healthcare sector is experiencing significant transformation due to artificial intelligence, particularly in medical imaging, which is crucial for breast cancer detection [2] - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million diagnoses and approximately 670,000 deaths reported by the WHO in 2022 [2] - In the U.S., the American Cancer Society estimates 316,950 new invasive breast cancer cases for the current year [2] Company Highlights - Izotropic Corporation is developing the IzoView Breast CT Imaging System, a 3D imaging solution designed to improve cancer detection accuracy, especially in women with dense breast tissue [3] - The company focuses on innovative technologies and imaging products for more accurate screening, diagnosis, and treatment of breast cancers [4]